Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. files periodic reports with the Securities and Exchange Commission as a publicly traded company listed on the New York Stock Exchange under ticker symbol BHC. The company also maintains a listing on the Toronto Stock Exchange. SEC filings provide detailed financial information, risk factors, business segment performance, and management discussion and analysis. Form 10-K annual reports offer comprehensive overviews of operations across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Quarterly Form 10-Q filings track financial performance throughout the fiscal year, breaking down revenue and profitability by therapeutic area and geographic region. Given the company's significant debt obligations, filings contain detailed disclosures regarding debt structure, maturity schedules, interest expenses, and refinancing activities. Form 8-K current reports disclose material events such as acquisitions, divestitures, executive changes, credit agreement amendments, and significant legal developments. Proxy statements (Form DEF 14A) provide information on corporate governance, executive compensation, board composition, and matters submitted for shareholder votes.
Patent litigation and intellectual property matters affecting key products like XIFAXAN receive disclosure in filings, as generic competition impacts future revenue streams. The company's relationship with Bausch + Lomb, in which it maintains a controlling interest, requires detailed segment reporting and potential disclosure of transactions between the entities. Regulatory compliance, manufacturing quality issues, and FDA enforcement actions would appear in SEC filings when material to investors. Debt covenant compliance, particularly given the company's leveraged capital structure, represents an important area of disclosure.
Investors use SEC filings to monitor trends in prescription volume, pricing dynamics, generic competition, research and development investments, and commercial strategy across therapeutic areas. Financial statements reveal capital allocation decisions, acquisition strategies, and operational efficiency across the diversified pharmaceutical portfolio. Risk factors sections outline threats including patent expirations, regulatory changes, reimbursement pressures, product liability, and competitive dynamics in pharmaceutical markets.
Seana Carson, EVP and General Counsel of Bausch Health Companies Inc. (BHC), reported two transactions in a Form 4. On 09/05/2025 the filing shows 51,337 shares were withheld to satisfy tax withholding obligations upon vesting of restricted share units at an indicated price of $7.35, leaving 512,955 shares beneficially owned. On 09/08/2025 the filing shows 13,370 shares sold in the open market pursuant to a Rule 10b5-1 plan at $7.31, reducing beneficial ownership to 499,585 shares.
The Form 4 is signed by an attorney-in-fact on behalf of the reporting person on 09/08/2025. Notes in the filing explicitly state the withholding was for tax obligations on RSU vesting and the sale was executed under a 10b5-1 plan adopted May 7, 2025.
Bausch Health Companies Inc (BHC) filed a Form 144 reporting a proposed sale of 13,370 common shares held at Fidelity Brokerage Services. The filing lists an aggregate market value of $97,734.70 and shows approximately 369,790,319 shares outstanding. The proposed sale is scheduled around 09/08/2025. The shares were acquired on 09/05/2025 through restricted stock vesting and were paid as compensation on the same date. The filer reports no other sales in the past three months and attests to the absence of undisclosed material adverse information.
Bausch Health Companies Inc. (BHC) is soliciting shareholder votes for a Special Meeting to ratify an Amended and Restated Shareholder Rights Plan (the "Rights Agreement"). Shareholders of record as of August 18, 2025 may vote at a virtual Special Meeting scheduled for October 7, 2025. The proxy materials were first mailed on or about August 27, 2025 and are available on the company website and regulatory filers.
The Rights Agreement creates transferable rights attached to each common share that, upon certain triggering events (the "Separation Time" following an "Acquiring Person" obtaining 20% of voting shares or other specified takeover events), become exercisable to purchase common shares at an Exercise Price equal to three times the Market Price (Market Price defined as the 20-day average closing price). The plan contains customary anti-dilution adjustments, a redemption price of $0.00001 per Right, carve-outs for Permitted/Competing Permitted Bids, a requirement to reconfirm the plan every third annual meeting, and other procedural and governance provisions. The filing states 369,800,365 common shares were outstanding as of August 18, 2025 and quorum requires holders of at least 25% of outstanding voting shares.
Lee Frank D., a director of Bausch Health Companies Inc. (BHC), reported the sale of 15,912 common shares in open-market transactions on 08/21/2025 at a weighted average price of $7.66 per share, reducing his beneficial ownership to 73,795 shares. The filing states the shares were sold to provide funds for estimated tax payments arising from a previously vested equity award granted to the issuer's non-employee directors. The reported price range for the multiple transactions was $7.66 to $7.665, and the Form 4 was signed by an attorney-in-fact on 08/22/2025.
Bausch Health Companies Inc (BHC) filed a Form 144 reporting a proposed sale of 15,912 common shares valued at $121,887.71. The shares were acquired on 05/12/2025 through restricted stock vesting as compensation from the issuer. The filer lists an approximate sale date of 08/21/2025 and the broker named is Fidelity Brokerage Services LLC with execution on the NYSE. The filing states there were 369,790,319 shares outstanding at the time and reports no securities sold by the filer in the prior three months. The notice includes the standard insider representation regarding absence of undisclosed material adverse information.
Bausch Health Companies Inc.'s Schedule 13D Amendment No. 7 reports that the group of Icahn-related reporting persons sold substantial holdings and now hold no beneficial interest in the issuer's common stock. On August 14, 2025, Icahn Partners LP sold 20,297,523 shares and Icahn Partners Master Fund LP sold 14,423,595 shares, each at a price of $9.00 per share (including brokerage fees). Following these transactions the reporting persons may be deemed to beneficially own 0 shares and have ceased to be beneficial owners of more than 5% of the class, removing their obligation to report under Rule 13d-1(a).
Paulson & Co. Inc. reports beneficial ownership of 70,755,869 common shares of Bausch Health Companies Inc., representing approximately 19.1% of the outstanding common shares based on 369,790,319 shares disclosed by the issuer. The stake is held through funds advised or managed by Paulson, which retain sole voting and dispositive power over these shares for reporting purposes, while Paulson disclaims direct pecuniary ownership except through those funds. The filing notes recent transactions are listed in an attached exhibit and identifies the issuer's principal executive office in Laval, Quebec. This amendment updates prior Schedule 13D disclosures and clarifies the reporting person’s role as investment manager.
John Paulson, through managed funds, acquired 34,721,118 shares of Bausch Health Companies Inc. at $9 per share on 08/14/2025, increasing the funds' reported beneficial ownership to 70,755,869 shares. The Form 4 shows the purchase was reported as an indirect holding by the Funds managed by Paulson, and the filing includes a standard disclaimer that Paulson disclaims beneficial ownership except for any pecuniary interest. The transaction reflects a sizable increase in reported stake via managed accounts.
Paulson & Co. Inc. reported an initial Form 3 disclosing that certain funds it manages hold 70,755,869 shares of Bausch Health Companies Inc. (BHC). The filing, dated 08/14/2025, lists Paulson as the investment manager and notes John Paulson as the controlling person; the shares are indirectly owned by the Funds.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
